Lido Advisors LLC Raises Position in Stryker Corporation $SYK

Lido Advisors LLC increased its position in shares of Stryker Corporation (NYSE:SYK) by 42.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,915 shares of the medical technology company’s stock after purchasing an additional 14,638 shares during the period. Lido Advisors LLC’s holdings in Stryker were worth $19,389,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Mid American Wealth Advisory Group Inc. acquired a new position in Stryker during the 2nd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at approximately $28,000. Sachetta LLC boosted its stake in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares in the last quarter. Ridgewood Investments LLC grew its holdings in Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after acquiring an additional 30 shares during the period. Finally, MTM Investment Management LLC acquired a new position in Stryker during the second quarter worth $38,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on SYK. Barclays raised their target price on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Tuesday, November 25th. BTIG Research reissued a “buy” rating and set a $410.00 price objective on shares of Stryker in a report on Friday, November 14th. Rothschild & Co Redburn initiated coverage on shares of Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $448.00 price target on shares of Stryker in a research report on Friday, November 14th. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Trading Down 0.3%

Shares of Stryker stock opened at $371.29 on Monday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The business has a 50 day moving average price of $368.90 and a 200 day moving average price of $380.22. The company has a market capitalization of $141.99 billion, a P/E ratio of 49.18, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the prior year, the firm earned $2.87 EPS. Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.